Literature DB >> 12566705

In vitro expression of human hepatitis B virus genomes carrying woodchuck hepatitis virus pre-S1 sequences.

Christophe Hourioux1, Jonas Kneser, Volker Bruss.   

Abstract

Many hepatitis B virus (HBV) in vivo experiments are unfeasible because this virus infects only humans. Former studies demonstrated that the pre-S1 domain of the viral envelope protein L determines host range. Therefore, we tried to generate HBV recombinants which might be able to infect woodchucks by exchanging different portions of the pre-S1 encoding gene with homologous parts from the related woodchuck hepatitis virus (WHV) in a cloned HBV genome. In 6 mutants, 11-92 N-terminal HBV pre-S1 codons were replaced by 20-120 codons from WHV. Four mutants carried C-terminal substitutions. The pre-S1 region overlaps with the viral polymerase gene, which is therefore also affected. After transfection of Huh7 cells, the DNA polymerase activity in cytoplasmic nucleocapsids was found to be only slightly affected. All mutants except for the largest C-terminal substitution allowed virion formation. Only the smallest N- and C-terminal substitutions had a wild-type phenotype. The remaining 7 variants allowed virion yields between 5 and 50% of that of the wild type. This demonstrated that substitution of up to 92 pre-S1 codons in an HBV genome with up to 120 codons from WHV pre- S1 was compatible with DNA replication and virion formation. Some recombinant viruses might be able to grow in woodchucks. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12566705     DOI: 10.1159/000067913

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  1 in total

1.  Persistence of the recombinant genomes of woodchuck hepatitis virus in the mouse model.

Authors:  Danzhen Pan; Yong Lin; Weimin Wu; Jingjiao Song; Ejuan Zhang; Chunchen Wu; Xinwen Chen; Kanghong Hu; Dongliang Yang; Yang Xu; Mengji Lu
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.